OXURION
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
OXURION
Industry:
Biotechnology Life Science Medical
Founded:
1991-01-01
Address:
Heverlee, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.oxurion.com
Total Employee:
51+
Status:
Active
Contact:
+32 16 75 13 10
Email Addresses:
[email protected]
Total Funding:
137.2 M EUR
Technology used in webpage:
SPF SSL By Default Microsoft Exchange Online Amazon Office 365 Mail Microsoft Microsoft Azure Network Solutions DNS Shutterstock Amazon Ireland Region
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Epacria Capital Partners
Epacria Capital Partners investment in Post-IPO Equity - Oxurion
Bareldam
Bareldam investment in Post-IPO Equity - Oxurion
Key Employee Changes
| Date | New article |
|---|---|
| 2020-10-14 | Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer |
Official Site Inspections
http://www.oxurion.com Semrush global rank: 3.84 M Semrush visits lastest month: 3.43 K
- Host name: nl1-ts109.a2hosting.com
- IP address: 185.146.22.243
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Oxurion"
Company - Oxurion
Oxurion is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy, the leading cause of vision loss in elderly …See details»
Oxurion - Biotech Research Company
Oxurion stands at the forefront of ophthalmic innovation, redefining approaches to treating Geographic Atrophy (GA). While many focus on genetic origins, we explore new horizons through cutting-edge CRISPR-based technology. Our …See details»
Oxurion Avoids Bankruptcy, Announces Board and …
Dec 28, 2023 Oxurion NV. Regulated information – Inside information. No bankruptcy filing. Significant reduction in Working Capital costs. Atlas commits to fund Oxurion’s Working Capital costs (including ...See details»
Oxurion - Crunchbase Company Profile & Funding
Organization. Oxurion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Oxurion is a biotech drug development company …See details»
Oxurion Avoids Bankruptcy, Announces Board and …
Dec 28, 2023 Oxurion NV Pascal Ghoson Chief Executive Officer Tel: +33 6 18 49 05 04 [email protected] : US Conway Communications Mary T. ConwaySee details»
Oxurion - Investors
Oxurion is a biopharmaceutical company developing next generation ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy, the leading cause of …See details»
Oxurion - Org Chart, Teams, Culture & Jobs - The Org
Oxurion (Euronext Brussels: OXUR - formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back …See details»
Oxurion NV (OXUR.BR) Company Profile & Facts - Yahoo Finance
See the company profile for Oxurion NV (OXUR.BR) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Oxurion NV Ends Reorganization, Reduces Debt | Nasdaq
Nov 5, 2024 Oxurion NV has successfully terminated its private judicial reorganization procedure after reaching amicable agreements with its key creditors, reducing its debt from €14.7 million …See details»
Oxurion Company Profile - Office Locations, Competitors ... - Craft
Oct 18, 2024 Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the …See details»
Oxurion Announces New Strategic Orientation to De-risk and …
Jan 22, 2024 Pascal Ghoson, CEO of Oxurion, states, “Oxurion today lays out its new corporate strategy, which is designed to further diversify and de-risk its ongoing activities. Starting March …See details»
Corporate Governance - Oxurion
Oxurion has adopted a Corporate Governance Charter, based on the Belgian Corporate Governance Code. The purpose of the corporate governance rules is to ensure efficient and …See details»
Oxurion NV Company Profile - Overview - GlobalData
Oxurion NV (Oxurion) is a biopharmaceutical company. It is dedicated to developing innovative therapies for retinal disorders, particularly Geographic Atrophy (GA). The company employs a …See details»
Oxurion NV (EBR:OXUR) Stock Price & Overview - Stock Analysis
4 days ago Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with …See details»
Postponement Annual Shareholders Meeting - Euronext Live
2 days ago Leuven, BELGIUM – April 4, 2025 – 02:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the …See details»
Oxurion signs a Letter of Intent and enters into exclusive …
Jul 8, 2024 Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production LEUVEN, BELGIUM - July 8, 2024 – …See details»
Shareholder Structure & History - Oxurion
May 30, 2006 Oxurion is listed on Euronext Brussels under the symbol OXUR. As of March 21th 2025, Oxurion has a total of 4.634.663 shares outstanding. The table below provides an …See details»
Oxurion to Acquire Majority Stake in Contract Research Organization
Mar 19, 2025 Oxurion NV is aiming to build the leading global franchise in the treatment of Age-related macular degeneration (AMD), based on the successful clinical development of its two …See details»
Oxurion renforce son Conseil d'Administration avec l'arrivée de …
Louvain, BELGIQUE – 14 février 2024 – 19h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce une évolution de son Conseil …See details»
Oxurion - Biotech Research Company
Chez Oxurion, notre mission est d'innover dans les traitements révolutionnaires qui préviennent la cécité et améliorent la vision des patients dans le monde entier. Spécialisés dans les maladies …See details»